Associate Scientist II, RNA Synthesis

Custom Field 1: 2362

Date: Sep 5, 2025

Location:

Cambridge, MA, US, 02142

This role is considered On-Site.

Overview:

The RNA Synthesis team is seeking a motivated individual to join our Annealing and Testing group as an Associate Scientist II. The Annealing and Testing group is responsible for the quality control of single stranded RNA using analytical techniques such as liquid chromatography and mass spectrometry. In addition the group is responsible for formulating high quality test articles (siRNA) to support research efforts across multiple therapeutic areas.

This position is onsite and will be located at our 675 W. Kendall St. location in Cambridge, MA.

Key Responsibilities:

Preparation of analytical samples.
Analysis of synthetic RNA using analytical techniques such as HPLC and MS, to confirm identity and determine purity of product.
Formulation and quality analysis of test articles (siRNA), by LCMS, UV spectroscopy and osmometry.
Perform Bacterial Endotoxin Test (BET).
Work closely with the team and cross-functionally to ensure required timelines are met.
Organize, analyze and interpret data for presentation to team members and larger audiences within the research organization.
Provide analytical support for various groups across research and early development, as needed.

Qualifications:

BS Chemistry, Biochemistry or related discipline with 0-2 years of work experience.
Experience with analytical instrumentation such as HPLC, LCMS, UV-VIS is required.
Experience in solid-phase synthesis of biomolecules is preferred.
Excellent written and oral communication skills, good organization skills, the ability to multitask, and the ability to work within a team and/or independently are required.
Complete record-keeping and excellent laboratory documentation practice (electronic notebook) are required.

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.